Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine Inc. (CMND) held its shareholder meeting on December 28, 2022, where all proposed matters were approved. This includes the company's rolling stock option plan and an increase in options and restricted share units available for issuance. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health issues, holding seven patent families and planning further acquisitions of intellectual property. The company aims to commercialize its products as regulated medicines, foods, or supplements.
Clearmind Medicine Inc. (CMND) announced its first first-in-human clinical trial in Israel for the MEAI-based CMND-100 compound targeting alcohol use disorder (AUD). The agreement with the IMCA center in Ramat Gan will be led by Prof. Mark Weiser. CMND plans to establish a similar agreement in the U.S.. AUD affects nearly 28 million adults in the U.S., with significant public health implications. The global AUD treatment market is projected to grow from $564 million in 2021, at an annual rate of 8.8% by 2032.
Clearmind Medicine has received a new patent from the U.S. Patent and Trademark Office for its proprietary MEAI as a substitute for alcoholic beverages. This patent complements similar patents granted in Europe and India, marking a significant milestone in a rapidly growing market for non-alcoholic options, valued at $395 million in the U.S. with a year-on-year growth of +20.6%. The company believes that this innovative compound can generate substantial revenue outside the pharmaceutical sector. The appointment of Nicholas Kadysh bolsters regulatory navigation for this product.
Clearmind Medicine Inc. (Nasdaq: CMND) updates shareholders on its progress towards FDA approval for its proprietary compound CMND-100, a treatment for Alcohol Use Disorder (AUD). The company has completed required non-clinical studies and is nearing its first human clinical trial. Clearmind is also exploring MEAI's potential for cocaine addiction and other mental health issues. The firm completed a $7.5 million U.S. IPO and uplisted to Nasdaq, enhancing its market presence. Future plans include advancing its IP portfolio and targeting new drug candidates for unmet medical needs.
Clearmind Medicine Inc. (CMND) has completed IND-enabling studies for its lead compound, CMND-100, targeting Alcohol Use Disorder (AUD). The company is preparing to submit an Investigational New Drug application to the FDA and the Israeli Ministry of Health, paving the way for its first human clinical trial. The compound is anticipated to significantly reduce alcohol consumption, addressing a critical global health issue that costs the U.S. $250 billion annually. Clearmind holds patents for CMND-100 in various regions, indicating strong intellectual property backing.
Clearmind Medicine (Nasdaq: CMND) has appointed Nicholas Kadysh, a former executive at Red Bull Canada and Juul Labs Canada, as a special advisor for the development of MEAI as an alcohol substitute. Kadysh brings extensive experience in regulatory issues, which is crucial as Clearmind conducts safety studies for its innovative drug candidate. The non-alcoholic beverage market is expanding, with U.S. sales growing by 21% over the past year, indicating a strong market opportunity for MEAI. Clearmind aims to develop MEAI as a therapeutic solution for addiction and an alternative to alcohol.
Clearmind Medicine Inc. (Nasdaq: CMND) has initiated the production of clinical batches for its psychedelic-derived drug candidate, CMND-100, aimed at treating Alcohol Use Disorder (AUD). The production follows successful synthesis development and complies with FDA GMP standards. This milestone supports their upcoming first-in-human clinical trial. Clearmind's non-clinical data suggests CMND-100 could address addiction challenges. The firm has also completed a pre-IND meeting with the FDA, indicating strong regulatory engagement.
Clearmind Medicine Inc. announces a successful $7.5 million underwritten public offering led by Aegis Capital Corp. as the sole bookrunner, aimed at uplisting to NASDAQ. The company is dedicated to developing psychedelic-derived therapeutics, focusing on health challenges such as alcohol use disorder. Currently, Clearmind possesses four patent families and aims to expand its intellectual property portfolio. The funds from this offering will support research and regulatory commercialization of their compounds.
Clearmind Medicine Inc. (CMND) has successfully closed an underwritten public offering of 1,153,847 common shares at a price of US$6.50 each, raising gross proceeds of US$7.5 million. This offering follows a 1-for-30 reverse stock split effective September 30, 2022. Aegis Capital Corp. has a 45-day option to purchase up to 173,077 additional shares, potentially bringing total proceeds to about US$8.6 million. The company focuses on developing novel psychedelic-derived therapeutics for major health issues, supported by a robust intellectual property portfolio.